MoonLake Immunotherapeutics (MLTX) Change in Account Payables (2021 - 2026)

MoonLake Immunotherapeutics' Change in Account Payables history runs 6 years deep, the most recent figure standing at -$6.2 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 304.88% year-over-year to -$6.2 million; the TTM figure through Mar 2026 stood at $11.4 million (up 33.45% YoY), while the FY2025 annual figure was $20.6 million, up 187.35% from the prior year.
• Change in Account Payables was -$6.2 million for Q1 2026 at MoonLake Immunotherapeutics, down from $4.3 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $8.2 million in Q3 2025 to a low of -$6.2 million in Q1 2026.
• Historically, Change in Account Payables has averaged $1.3 million across 5 years, with a median of $1.6 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables plunged 460.19% in 2023, then surged 682.92% in 2024.
• A 5-year view of Change in Account Payables shows it stood at -$801281.0 in 2022, then sank by 95.53% to -$1.6 million in 2023, then slipped by 9.65% to -$1.7 million in 2024, then jumped by 348.54% to $4.3 million in 2025, then tumbled by 244.57% to -$6.2 million in 2026.
• The last three Change in Account Payables figures came in at -$6.2 million (Q1 2026), $4.3 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.